Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.72 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.72 |
| ▸ | CALCR | P30988 | 3/20 | 0.68 |
| ▸ | GLP1R | P43220 | 10/20 | 0.63 |
| ▸ | GCGR | P47871 | 8/20 | 0.63 |
| ▸ | GIPR | P48546 | 5/20 | 0.62 |
| ▸ | NPY2R | P49146 | 4/20 | 0.61 |
| ▸ | NPY4R | P50391 | 4/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182808 | 0.92 | CALCR (0.69) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL30495724 | 0.92 | CALCR (0.66) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL29949425 | 0.91 | CALCR (0.67) | CRHR1CRHR2CALCRGLP1RNPY2R | |
| SCHEMBL31068602 | 0.91 | CALCR (0.73) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL31182688 | 0.91 | CALCR (0.71) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL31182700 | 0.91 | CALCR (0.68) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL31182551 | 0.91 | CALCR (0.68) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL30495828 | 0.91 | CALCR (0.74) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL30358145 | 0.91 | CALCR (0.68) | CRHR1CRHR2CALCRGLP1RGCGR | |
| SCHEMBL30658233 | 0.90 | CALCR (0.71) | CRHR1CRHR2CALCRGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395486-A1 | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-15 | — | — | US | claimed |
| US-11266626-B2 | Reduction of ER-MAM-localized APP-C99 and methods of treating alzheimer's disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | LONZA AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-27 | — | — | US | disclosed |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | LONZA LTD (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-3833622-B1 | TRANSFER STATION FOR API SEED CRYSTALS | LONZA AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12497624-B2 | Methods for improving production of biological products by reducing the level of endogenous protein | LONZA LTD (CH) | 2025-12-16 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4638756-A1 | HOST CELLS WITH PAT1 KNOCKOUT FOR INCREASED SPECIFIC PROTEIN PRODUCTIVITY | Lonza Ltd. (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320446-A1 | METHOD AND SYSTEM FOR PROVIDING BUFFER SOLUTIONS | LONZA AG (CH) | 2025-10-16 | — | — | US | disclosed |
| WO-2022069613-A1 | HOST CELLS OVEREXPRESSING TRANSLATIONAL FACTORS | LONZA LTD (CH) | 2022-04-07 | — | — | WO | disclosed |
| EP-3874047-B1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA AG (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| US-11266626-B2 | Reduction of ER-MAM-localized APP-C99 and methods of treating alzheimer's disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | CRHR1 3109/4885CRHR2 3761/4885CALCR 855/4885 |
| US-12534511-B2 | Serum albumin-binding fibronectin type III domains | FN1, ALB, FGB | CRHR1 2659/4885CRHR2 3474/4885CALCR 4107/4885 |
| US-20260062709-A1 | METHODS FOR IMPROVING PRODUCTION OF BIOLOGICAL PRODUCTS BY REDUCING THE LEVEL OF ENDOGENOUS PROTEIN | MRPL21, SET, RPS27A | CRHR1 3724/4885CRHR2 3475/4885CALCR 2051/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | CRHR1 3233/4885CRHR2 2112/4885CALCR 1319/4885 |
| US-12529088-B2 | Helper factors for expressing proteins in yeast | UPF1, ILF3, YIF1A | CRHR1 2736/4885CRHR2 2610/4885CALCR 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.